Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags
Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.
You may also be interested in...
Pfizer's vaccine for COVID-19 outpaced expectations on efficacy, driving a stock market rally and garnering reaction from Vice President Pence and President-elect Biden.
The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.